946000-27-7

Basic information

• Product Name: 4-BroMo-2-(diMethylaMino)pyridine
• Synonyms: 4-BroMo-2-(diMethylaMino)pyridine;4-broMo-N,N-diMethylpyridin-2-aMine;(4-BroMo-pyridin-2-yl)-diMethyl-aMine
• CAS NO: 946000-27-7
• Molecular Formula: C7H9BrN2
• Molecular Weight: 201.06376
• Product Categories: Heterocycle-Pyridine series
• Mol File: 946000-27-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 278.4±20.0 °C(Predicted)
• Appearance: /
• Density: 1.469±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 6.76±0.10(Predicted)
• CAS DataBase Reference: 4-BroMo-2-(diMethylaMino)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-2-(diMethylaMino)pyridine(946000-27-7)
• EPA Substance Registry System: 4-BroMo-2-(diMethylaMino)pyridine(946000-27-7)

Safety Data

• Hazardous Substances Data: 946000-27-7(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-(dimethylamino)pyridine is a chemical compound with the molecular formula C8H10BrN2. It is a pyridine derivative that contains a bromine atom and a dimethylamino group. 4-BroMo-2-(diMethylaMino)pyridine is commonly used as a reagent in organic synthesis, particularly in the formation of C-N bonds. It is also utilized as a building block in the pharmaceutical and agrochemical industries for the synthesis of various drug candidates and bioactive molecules. Additionally, 4-Bromo-2-(dimethylamino)pyridine has been studied for its potential applications in materials science, such as in the development of organic electronics and light emitting diodes. Due to its versatile reactivity and wide-ranging applications, this compound is a valuable tool for chemists and researchers in various fields.

Upstream product

• 128071-98-7 4-bromo-2-fluoropyridine 
• 124-40-3 dimethyl amine 
• 84249-14-9 2-amino-4-bromopyridine 
• 74-88-4 methyl iodide 
• 50-00-0 formaldehyd 

Relevant articles and documents

Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors

Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD) and Down's syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A's role as a mediator in the cell cycle has garnered interest in oncologic indications. Structure-activity relationship (SAR) analysis in combination with high-resolution X-ray crystallography leads to a series of pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochemical properties, and a high degree of selectivity over the kinome. Compound 11 exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of new therapies for the treatment of diseases linked to DYRK1A function.

IMIDAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS

New imidazopyridmin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use as inhibitors of Janus Kinases (JAK) for the treatment of myeloproliferative disorders, leukemia, lymphoid malignancies and solid tumors; bone marrow and organ transplant rejection; immune-mediated diseases and inflammatory diseases.

NOVEL COMPOUNDS

The invention provides novel hydantoin derivatives; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.